Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Characterization of PSP and venlafaxine modulation
DRKS00025481Phase 2Completed
- Sponsor
- Deutsche Forschungsgemeinschaft
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venlafaxine in progressive supranuclear palsy (PSP), sponsored by Deutsche Forschungsgemeinschaft. Started Feb 2022; status: completed.
02
Drugs
venlafaxine
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on DRKS00025481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00025481.